Dilon Diagnostics Gamma-Guided Localization System Cleared by FDA

Share Article

GammaLōc® Helps Locate Breast Lesions Quickly and Accurately for Biopsy

This recent innovation helps physicians improve patient management and confidently deliver faster, more accurate results to their anxious patients.

Past News Releases

RSS

Dilon Diagnostics announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its lesion-localization system for molecular imaging biopsy guidance.

GammaLōc® is a complementary technology to Dilon’s cornerstone product, the Dilon 6800 Gamma Camera. The GammaLōc® (GL) system will help doctors accurately locate breast lesions and enable gamma-guided biopsies, particularly useful for patients that have findings on the Dilon system that are not revealed with other imaging modalities.

The GammaLōc® system utilizes a CorreLocator™ paddle and a StereoView™ imaging collimator system - a technique similar to that used in stereotactic X-ray localization, and the GammaLōc® software calculates the specific location of the suspect lesion. The compact design allows for breast biopsies with optimal patient comfort; and the entire system is small and portable, allowing physicians to perform molecular imaging guided biopsy procedures anywhere on site.

“Thanks to the superior performance of the Dilon 6800 camera combined with this new biopsy-guidance capability, physicians will find it easier to locate suspicious lesions seen with molecular breast imaging, greatly facilitating and expediting the biopsy process,” said Robert Moussa, President and CEO of Dilon Diagnostics. “This recent innovation helps physicians improve patient management and confidently deliver faster, more accurate results to their anxious patients.”

About Dilon Diagnostics:
Dilon Diagnostics, a brand of Dilon Technologies Inc. is bringing innovative new medical imaging products to market. Dilon’s cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Technologies please visit http://www.dilon.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nancy F. Morter
Visit website